EBV Conference 2008 Guangzhou - Baylor College of Medicine

207 (RegID: 1526)
Patrice MORAND
Institution: University Hospital Grenoble
e-mail: PMorand@chu-grenoble.fr
EVALUATION OF 3 NEW VIDAS TESTS FOR THE DETECTION OF EPSTEIN-BARR VIRUS
VCA IGM, VCA/EA IGG AND EBNA IGG ANTIBODIES IN HUMAN SERUM SAMPLES
M. Baccard, A. Foussadier, L. Allard, P. Desmottes, P. Morand, J.M. Seigneurin
Posterabstract:
Objectives:
The aim of the study was to evaluate the performance of 3 new automated VIDAS EBV diagnostic tests
for the determination of the patient EBV serological status. The EBV reagents currently under
development on VIDAS instrument are aimed to detect immunoglobulins against Viral Capsid Antigen
(VCA), Early Antigen (EA) and Epstein-Barr nuclear antigen (EBNA) : VIDAS VCA IgM, VIDAS
VCA/EA IgG and VIDAS EBNA IgG. Sensitivities and specificities were determined on characterized
sera samples for each of the 3 tests.
Methods:
VIDAS EBV VCA/EA IgG and EBNA IgG tests are based on indirect sandwich format, with peptides
coated on the solid phase. VIDAS EBV VCA IgM test is based on immunocapture with labelled peptides
as revelation phase.
Fifty seven serum samples from EBV negative individuals, 109 from EBV primary infection and 93 from
EBV past infection were tested on VIDAS. EBV clinical status was initially established using 2 microtiter
plates tests: Dade Behring, which detects EBV IgM and EBV IgG, and BMD for the specific detection of
EBNA IgG. Discrepant results were analysed using IF.
Results:
On characterized serum samples, the sensitivities of VIDAS VCA IgM, VCA/EA IgG and EBNA IgG
were 97.5 % [93.6 – 99.0%], 95.9 % [92.0 –97.9%] and 98.1 % [93.2- 99.5%] respectively and the
specificities of VIDAS VCA IgM , VCA/EA IgG and EBNA IgG were 95.2 % [88.2 – 98.2%], 100 %
[93.4 – 100%] and 96.5 % [91.9 – 98.5%] respectively.
Conclusions:
The new VIDAS EBV reagents presented good performance in accordance with the patients’ serological
status established with the other immunoassay methods. VIDAS EBV reagents will be a good alternative
to currently used manual method for Infectious Mononucleosis determination, enabling single testing as
well as series.
EBV Conference 2008 Guangzhou
- 281 -